Oprozomib in patients with newly diagnosed multiple myeloma

被引：16

作者：

Hari, Parameswaran ^{[1
]}

Matous, Jeffrey V. ^{[2
]}

Voorhees, Peter M. ^{[3
]}

Shain, Kenneth H. ^{[4
]}

Obreja, Mihaela ^{[5
]}

Frye, John ^{[5
]}

Fujii, Hisaki ^{[5
]}

Jakubowiak, Andrzej J. ^{[6
]}

Rossi, Davide ^{[7
]}

Sonneveld, Pieter ^{[8
]}

机构：

[1] Med Coll Wisconsin, Milwaukee, WI 53226 USA

[2] Colorado Blood Canc Inst, Denver, CO USA

[3] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA

[4] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[5] Amgen Inc, Thousand Oaks, CA 91320 USA

[6] Univ Chicago, Med Ctr, Chicago, IL 60637 USA

[7] Univ Piemonte Orientale, Novara, Italy

[8] Erasmus MC Canc Inst, Rotterdam, Netherlands

来源：

BLOOD CANCER JOURNAL | 2019年 / 9卷 / 9期

关键词：

DEXAMETHASONE; CARFILZOMIB; CYCLOPHOSPHAMIDE; LENALIDOMIDE; MULTICENTER;

D O I：

10.1038/s41408-019-0232-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：4

共 10 条

[1] A Multicenter, Open-Label, Phase 1b Study of Carfilzomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients (CHAMPION-2)
Boccia, Ralph V.
Bessudo, Alberto
Agajanian, Richy
Conkling, Paul
Harb, Wael
Yang, Hui
Pinchasik, Dawn
Kimball, Amy S.
Berenson, James R.
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (07) : 433 - 437
[2] Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study
Bringhen, Sara
Petrucci, Maria Teresa
Larocca, Alessandra
Conticello, Concetta
Rossi, Davide
Magarotto, Valeria
Musto, Pellegrino
Boccadifuoco, Luana
Offidani, Massimo
Omede, Paola
Gentilini, Fabiana
Ciccone, Giovannino
Benevolo, Giulia
Genuardi, Mariella
Montefusco, Vittorio
Oliva, Stefania
Caravita, Tommaso
Tacchetti, Paola
Boccadoro, Mario
Sonneveld, Pieter
Palumbo, Antonio
[J]. BLOOD, 2014, 124 (01) : 63 - 69
[3] Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies
Cavaletti, Guido
Jakubowiak, Andrzej J.
[J]. LEUKEMIA & LYMPHOMA, 2010, 51 (07) : 1178 - 1187
[4] Myeloma: management of the newly diagnosed high-risk patient
Dispenzieri, Angela
[J]. HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2016, : 485 - 494
[5] Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
Ghobrial, Irene M.
Badros, Ashraf Z.
Vredenburgh, James J.
Matous, Jeffrey
Caola, Aaron M.
Savell, Alexandra
Henrick, Patrick
Paba-Prada, Claudia E.
Schlossman, Robert L.
Laubach, Jacob P.
Rosenblatt, Jacalyn
Yee, Andrew
Wisch, Jeffrey S.
Farber, Charles M.
Maegawa, Rodrigo O.
Usmani, Saad Z.
Cappuccio, Joseph
Rivotto, Bradley
Noonan, Kimberly
Reyes, Kaitlen
Munshi, Nikhil C.
Anderson, Kenneth C.
Richardson, Paul
[J]. BLOOD, 2016, 128 (22)
[6] Hari P.N., 2014, Blood, V124, P3453, DOI DOI 10.1182/BLOOD.V124.21.3453.3453
[7] A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
Jakubowiak, Andrzej J.
Dytfeld, Dominik
Griffith, Kent A.
Lebovic, Daniel
Vesole, David H.
Jagannath, Sundar
Al-Zoubi, Ammar
Anderson, Tara
Nordgren, Brian
Detweiler-Short, Kristen
Stockerl-Goldstein, Keith
Ahmed, Asra
Jobkar, Terri
Durecki, Diane E.
McDonnell, Kathryn
Mietzel, Melissa
Couriel, Daniel
Kaminski, Mark
Vij, Ravi
[J]. BLOOD, 2012, 120 (09) : 1801 - 1809
[8] Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma
Korde, Neha
Roschewski, Mark
Zingone, Adriana
Kwok, Mary
Manasanch, Elisabet E.
Bhutani, Manisha
Tageja, Nishant
Kazandjian, Dickran
Mailankody, Sham
Wu, Peter
Morrison, Candis
Costello, Rene
Zhang, Yong
Burton, Debra
Mulquin, Marcia
Zuchlinski, Diamond
Lamping, Liz
Carpenter, Ashley
Wall, Yvonne
Carter, George
Cunningham, Schuyler C.
Gounden, Verena
Sissung, Tristan M.
Peer, Cody
Maric, Irina
Calvo, Katherine R.
Braylan, Raul
Yuan, Constance
Stetler-Stevenson, Maryalice
Arthur, Diane C.
Kong, Katherine A.
Weng, Li
Faham, Malek
Lindenberg, Liza
Kurdziel, Karen
Choyke, Peter
Steinberg, Seth M.
Figg, William
Landgren, Ola
[J]. JAMA ONCOLOGY, 2015, 1 (06) : 746 - 754
[9] Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma
Shah, Jatin J.
Stadtmauer, Edward A.
Abonour, Rafat
Cohen, Adam D.
Bensinger, William I.
Gasparetto, Cristina
Kaufman, Jonathan L.
Lentzsch, Suzanne
Vogl, Dan T.
Gomes, Christina L.
Pascucci, Natalia
Smith, David D.
Orlowski, Robert Z.
Durie, Brian G. M.
[J]. BLOOD, 2015, 126 (20) : 2284 - 2290
[10] Design and Synthesis of an Orally Bioavailable and Selective Peptide Epoxyketone Proteasome Inhibitor (PR-047)
Zhou, Han-Jie
Aujay, Monette A.
Bennett, Mark K.
Dajee, Maya
Demo, Susan D.
Fang, Ying
Ho, Mark N.
Jiang, Jing
Kirk, Christopher J.
Laidig, Guy J.
Lewis, Evan R.
Lu, Yan
Muchamuel, Tony
Parlati, Francesco
Ring, Eileen
Shenk, Kevin D.
Shields, Jamie
Shwonek, Peter J.
Stanton, Timothy
Sun, Congcong M.
Sylvain, Catherine
Woo, Tina M.
Yang, Jinfu
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (09) : 3028 - 3038

← 1 →